UNSPSC 51112606: Lomustine

This classification denotes a nitrosourea compound with the molecular formula C9H16ClN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7BRF0Z81KG, chemically known as 1-nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl- but more generally known as lomustine, which bears US NIH Compound Identifier 3950. European Medicines Agency schedules Lomustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08567MIG.

UNSPSC 51112606 Lomustine, a Commodity code, encompasses the procurement of this specific chemotherapy agent — a nitrogen mustard alkylating agent used in cancer treatment, particularly for brain tumors and lymphomas — by state and local health agencies. The single recent opportunity in the dataset shows state health and human services commissions using this code within the context of pharmacy benefit management and direct-to-manufacturer prescription programs rather than as a traditional pharmaceutical commodity buy. State and local procurement of lomustine typically flows through health plans administered by departments of health and human services, Medicaid agencies, and prison health systems. The Texas Health and Human Services Commission's April 2026 RFI on direct-to-manufacturer prescriptions signals a shift toward bypass models that negotiate directly with pharmaceutical suppliers outside traditional pharmacy benefit managers and group purchasing organizations, which may reshape how states source specialty chemotherapy agents like lomustine.

Activity under this code is sparse in the recent-opportunities dataset. The Texas HHS Commission issued RFI No. HHS0017013 on March 27, 2026, with a response deadline of April 3, 2026, to gather vendor capabilities and market intelligence on establishing direct pharmacy relationships and implementing negotiated net pricing models without rebates for prescription fulfillment. The RFI does not commit to specific contract values, durations, or set-asides at this exploratory stage but indicates Texas's intent to develop detailed procurement specifications and implementation timelines for subsequent formal RFPs following the information-gathering phase. Beyond this single Texas solicitation, the code shows no other recent state or local lomustine procurement activity in the dataset, suggesting either highly consolidated purchasing through federal or multi-state cooperative channels, or limited visibility into specialty pharmaceutical procurement at the state and local level.